| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 21.119 | 27.372 | 36.460 | 40.347 | 39.542 | 68.506 | 91.594 | 94.120 | 84.456 | 109.086 |
| Total Income - EUR | 21.119 | 27.372 | 36.460 | 40.347 | 39.542 | 68.506 | 91.594 | 94.120 | 84.456 | 109.086 |
| Total Expenses - EUR | 9.877 | 37.504 | 26.589 | 33.846 | 30.979 | 30.147 | 31.687 | 33.489 | 39.708 | 27.470 |
| Gross Profit/Loss - EUR | 11.243 | -10.132 | 9.870 | 6.502 | 8.563 | 38.359 | 59.907 | 60.631 | 44.749 | 81.616 |
| Net Profit/Loss - EUR | 10.609 | -10.680 | 7.187 | 6.098 | 8.168 | 37.674 | 59.105 | 59.830 | 43.946 | 78.352 |
| Employees | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Embryomed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 107 | 31.003 | 30.428 | 33.200 | 27.827 | 21.878 | 17.300 | 10.080 | 8.799 | 9.663 |
| Current Assets | 12.893 | 4.618 | 5.421 | 4.511 | 7.010 | 54.841 | 109.408 | 147.598 | 137.032 | 88.775 |
| Inventories | 0 | 0 | 0 | 1.530 | 32 | 686 | 671 | 673 | 0 | 0 |
| Receivables | 1.339 | 2.004 | 4.460 | 1.844 | 1.808 | 6.586 | 5.004 | 1.436 | 1.492 | 79.216 |
| Cash | 11.554 | 2.615 | 961 | 1.137 | 5.170 | 47.569 | 103.732 | 145.489 | 135.540 | 9.559 |
| Shareholders Funds | 12.235 | 1.430 | 8.593 | 14.534 | 22.420 | 37.724 | 95.992 | 121.191 | 103.099 | 78.396 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 766 | 34.191 | 27.256 | 23.176 | 12.417 | 38.995 | 30.716 | 36.487 | 42.731 | 20.043 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Embryomed Srl